Download PDF
Viszeralchirurgie 2003; 38(6): 366-373
DOI: 10.1055/s-2003-45504
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Präoperative Diagnostik bei gastrointestinalen Stromatumoren

Preoperative Diagnostic Procedures in Gastrointestinal Stromal TumorsJ.  Schütte1 , G.  Antoch2
  • 1Klinik für Onkologie/Hämatologie, Marien Hospital Düsseldorf, Düsseldorf
  • 2Institut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Essen
Further Information

Publication History

Publication Date:
15 December 2003 (online)

    Permissions and Reprints

Zusammenfassung

Die präoperative Diagnostik gastrointestinaler Stromatumoren (GIST) zur Bestimmung der Tumorausdehnung und der Resektabilität entspricht weitgehend der Diagnostik anderer Tumoren des Gastrointestinaltrakts. Komplexer ist die bildgebende Verlaufsbeobachtung des Therapieansprechens während einer präoperativen Induktionstherapie mit Imatinib bei primär nicht im Gesunden resektablen GIST. Die Positronenemissionstomographie (PET) ist derzeit die Methode der Wahl, um ein (funktionelles) Therapieansprechen frühzeitig und mit hoher Genauigkeit erkennen zu können, ist aber nur eingeschränkt verfügbar. Computertomographisch ermittelte (morphologische) Surrogatparameter scheinen mit dem PET-Ansprechen zu korrelieren, bedürfen jedoch noch der Validierung in prospektiven Studien.

Abstract

Preoperative diagnostic procedures in patients with gastrointestinal stromal tumors (GIST) for the assessment of tumor exten-sion and resectability resemble the diagnostic of other gastrointestinal tumors. More challenging, however, is the evaluation of treatment response during preoperative induction therapy with imatinib in patients with primarily irresectable GIST. Positron emission tomography (PET) is the diagnostic tool of choice with a high sensitivity and specifity for the evaluation of treatment response but is not readily available. Alternatively, computed tomography (CT) may provide surrogate parameters which correlate well with the PET response but require further evaluation in prospective studies.

Schlüsselwörter

Gastrointestinale Stromatumoren - GIST - Diagnostik - Computertomographie - PET

Key words

Gastrointestinal stromal tumor - GIST - diagnosis - computed tomography - PET

Literatur

  • 1 De Matteo R P, Lewis J J, Leung D, Mudan S S, Woodruff J M, Brennan M F. Two hundred gastrointestinal stromal tumors.  Ann Surg. 2000;  231 51-58
    CrossrefPubMedGoogle Scholar
  • 2 Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.  Virchov Arch. 2001;  438 1-12
    CrossrefPubMedGoogle Scholar
  • 3 Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumours.  Ann Chir Gynaecol. 1998;  87 278-281
    Google Scholar
  • 4 O'Leary T, Berman J. Gastrointestinal stromal tumors: Answers and Questions.  Hum Pathol. 2002;  33 456-459
    CrossrefPubMedGoogle Scholar
  • 5 Fletcher C DM, Berman J J, Corless C, Gorstein F, Lasota J, Longley B J, Miettinen M, O'Leary T J, Remotti H, Rubin B P, Shmookler B, Sobin L H, Weiss S W. Diagnosis of gastrointestinal stromal tumors: a consensus approach.  Hum Pathol. 2002;  33 459-465
    Google Scholar
  • 6 Graadt van Roggen J F, van Velthuysen M LF, Hogendoorn P CW. The histopathological differential diagnosis of gastrointestinal stromal tumors.  J Clin Pathol. 2001;  54 96-103
    CrossrefPubMedGoogle Scholar
  • 7 Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours.  J Pathol. 2001;  193 505-510
    PubMedGoogle Scholar
  • 8 Andersson J, Sjögren H, Meis-Kindblom J M, Stenman G, Aman P, Kindblom L. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors.  Am J Pathol. 2002;  160 15-23
    PubMedGoogle Scholar
  • 9 Lasota J, Lasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas.  Am J Surg Pathol. 1999;  154 53-60
    PubMedGoogle Scholar
  • 10 Rubin B P, Singer S, Tsao C, Duensing A, Lux M, Ruiz R, Hibbard M K, Chen C, Xiao S, Tuveson D A, Demetri G D, Fletcher C DM, Fletcher J A. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.  Cancer Res. 2001;  61 8118-8121
    PubMedGoogle Scholar
  • 11 Corless C L, Mc Greevey L, Haley A, Town A, Heinrich M. KIT mutations are common in incidental gastrointestinal stromal tumors one centimetre or less in size.  Am J Pathol. 2002;  160 1567-1572
    CrossrefPubMedGoogle Scholar
  • 12 Heinrich M C, Corless C L, Blanke C, Demetri G D, Joensuu H, von Mehren M, Mc Greevey L S, Wait C L, Griffith D, Chen C J, Haley A, Kiese B, Druker B, Roberts P, Eisenberg B, Singer S, Silberman S, Dimitrijevic S, Fletcher C D, Fletcher J A. KIT mutational status predicts clinical response to STI 571 in patients with metastatic gastrointestinal stromal tumors (GISTs).  Proc Am Soc Clin Oncol. 2002;  21 2a
    PubMedGoogle Scholar
  • 13 Lux M, Rubin B, Biase T L, Chen C, Maclure T, Demetri G, Xiao S, Singer S, Fletcher D DM, Fletcher J A. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.  Am J Surg Pathol. 2000;  156 791-795
    PubMedGoogle Scholar
  • 14 Ng E H, Pollock R E, Romsdahl M M. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas.  Cancer. 1992;  69 (6) 1334-1341
    PubMedGoogle Scholar
  • 15 Mudan S S, Conlon K C, Woodruff J M, Lewis J J, Brennan M. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection.  Cancer. 2000;  88 66-74
    CrossrefPubMedGoogle Scholar
  • 16 Eilber F C, Rosen G, Forscher C, Nelson S D, Dorey F, Eilber F R. Recurrent gastrointestinal stromal sarcomas.  Surg Oncol. 2000;  9 71-75
    CrossrefPubMedGoogle Scholar
  • 17 Eilber F C, Rosen G, Forscher C, Nelson S D, Dorey F J, Eilber F R. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas.  Ann Surg Oncol. 1999;  6 645-650
    CrossrefPubMedGoogle Scholar
  • 18 Buemming P, Meis-Kindblom J M, Kindblom L G, Gustavsson B, Thakrar B, Engstrom K, Ahlman H, Nilsson B E. Is there an indication for adjuvant treatment with imatinib mesylate in patients with aggressive gastrointestinal stromal tumors (GISTs)? Abstr 3289.  Proc Am Soc Clin Oncol. 2003;  22 818
    PubMedGoogle Scholar
  • 21 Bauer S, Schütte J. Gastrointestinale Stromatumoren. In: Seeber S, Schütte J (Hrsg) Therapiekonzepte Onkologie. Berlin; Springer 2003: 809-826
    Google Scholar
  • 22 Benjamin R S, Rankin C, Fletcher C, Blanke C, Von Mehren M, Maki R, Bramwell V, Baker L, Borden E, Demetri G D. for the Sarcoma Intergroup . Phase III dose-randomized study of imatinib mesylate (STI 571) for GIST: Intergroup S0033 early results. Abstr 3271.  Proc Am Soc Clin Oncol. 2003;  22 814
    PubMedGoogle Scholar
  • 23 Verweij J, Casali P G, Zalcberg J, Le Cesne A, Reichard P, Blay J Y, Issels R D, Van Glabbeke M, Donato Di Paola E, Judson I R. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Abstr 3272.  Proc Am Soc Clin Oncol. 2003;  22 814
    PubMedGoogle Scholar
  • 24 Kindblom L G. Gastrointestinal Stromal Tumors: Current Management and Future Challenges. ASCO Virtual Meeting 2003 http://www. asco.org/ac/1,1003,_12-002511-00_18-0023-00_19-00875-00_ 21-0011,00.asp
  • 25 Blanke C D. Gastrointestinal Stromal Tumors: Current Management and Future Challenges. ASCO Virtual Meeting 2003 http://www.asco. org/ac/1,1003,_12-002511-00_18-0023-00_19-00707-00_ 21-0011,00.asp
  • 26 Van den Abbeele A D, Badawi R D, Cliché J, Janicek J, Tetrault R, Spangler T, Potter A, Merriam P, Silberman S, Dimitrijevic S, Demetri G D. 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST).  Proc Am Soc Clin Oncol. 2002;  21 403a
    PubMedGoogle Scholar
  • 27 Kanja J, Bauer S, Schütte J, Bokisch A. Evaluation of the therapy response with STI 571 in metastatic gastrointestinal stromal tumor (GIST) by [18F]-FDG-PET.  J Cancer Res Clin Oncol. 2002;  128 (Suppl 1) S 136
    PubMedGoogle Scholar
  • 28 De Matteo R P, Heinrich M C, El-Rifai W M, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571.  Hum Pathol. 2002;  33 466-477
    CrossrefPubMedGoogle Scholar
  • 29 Van den Abbeele A D. for the GIST Collaborative PET Study . F18-FDG-PET Provides Early Evidence of Biological Response to STI 571 in Patients with Malignant Gastrointestinal Stromal Tumors (GIST).  Proc Am Soc Clin Oncol. 2003;  22 (abstr) 1444
    PubMedGoogle Scholar
  • 30 Choi H, Charnsangavej C, Macapinlac H A, Burgess M A, Patel S R, Chen L L, Podoloff D A, Benjamin R S. Correlation of computerized tomography (CT) and proton emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate. Abstr 3290.  Proc Am Soc Clin Oncol. 2003;  22 819
    PubMedGoogle Scholar
  • 31 Antoch G, Freudenberg L S, Bauer S, Kuehl H, Renzing-Koehler K, Goerges R, Schuette J, Bockisch A, Debatin J F, Kanja J. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of Imatinib (STI 571) therapy in patients with gastrointestinal stromal tumors.  J Nucl Med in press
  • 32 Choi H, Faria S C, Podoloff D A, Macapinlac H A, Charnsangavej C. Monitoring treatment effects of STI-571 on gastrointestinal stromal tumors (GIST) with CT and PET: A quantitative analysis.  Radiology. 2002;  225 583
    CrossrefPubMedGoogle Scholar
  • 33 Chen M YM, Bechtold R E, Savage P D. Cystic changes in hepatic metastases from gastrointestinal strom tumors.  Am J Roentgenol. 2002;  179 1059-1062
    PubMedGoogle Scholar
  • 34 Van den Abbeele A D, Badawi R D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).  Eur J Cancer. 2002;  38 (Suppl 5) S 60-S 65
    PubMedGoogle Scholar
  • 35 Stroobants S, Goeminne J, Seegers M. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec(R)).  Eur J Cancer. 2003;  39 2012-2020
    CrossrefPubMedGoogle Scholar
  • 36 Reddy M P, Reddy P, Lilien D L. F-18 FDG PET imaging in gastrointestinal stromal tumor.  Clin Nucl Med. 2003;  28 677-679
    CrossrefPubMedGoogle Scholar
  • 37 Bauer S, Corless C L, Heinrich M C, Dirsch O, Antoch G, Kanja J, Seeber S, Schutte J. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.  Cancer Chemother Pharmacol. 2003;  51 261-265
    PubMedGoogle Scholar
  • 38 Young H, Baum R, Cremerius U. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.  Eur J Cancer. 1999;  35 1773-1782
    CrossrefPubMedGoogle Scholar
  • 39 Van den Abbeele A D, Badawi R D, Cliché J P, Janicek M J, Tetrault R, Spangler T, Potter A, Merriam P, Silberman S, Dimitrijevic S, Demetri G D. 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST).  Proc Am Soc Clin Oncol. 2003;  22 (abstr) 1610
    PubMedGoogle Scholar
  • 40 WHO handbook of reporting results of cancer treatment .Geneva; World Health Organization Offset Publication No. 48 1979
  • 41 Therasse P, Arbuck S G, Eisenhauer E A. et al . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.  J Natl Cancer Inst. 2000;  92 205-216
    CrossrefPubMedGoogle Scholar
  • 42 Hohenberger P, Bauer S, Schneider U, Pinlk D, Dirsch O, Schuette J, Reichardt P. Tumor resection following imatinib pretreatment in GI stromal tumors.  Proc Am Soc Clin Oncol. 2003;  22 818
    PubMedGoogle Scholar
  • 43 Bauer S, Lang H, Niebel W, Erhardt J, Dirsch O, Gauler T, Bojko P, Seeber S, Flasshove M, Schütte J. Resection of residual disease in patients with gastrointestinal stromal tumors after treatment with imatinib.  Onkologie. 2003;  5 (Suppl.) 32
    PubMedGoogle Scholar
  • 44 Pierie J EN, Muzikansky A, Yeap B Y, Souba W W, Ott M J. The effect of surgery and outcome of gastrointestinal stromal tumors.  Arch Surg. 2001;  136 383-389
    CrossrefPubMedGoogle Scholar

Prof. Dr. J. Schütte

Klinik für Onkologie/Hämatologie, Marien Hospital Düsseldorf, Interdisziplinäres Onkologisches Zentrum

Rochusstraße 2

40479 Düsseldorf

Phone: + 49-211-4400-2501

Fax: + 49-211-4400-2210

Email: jochen.schuette@uni-essen.de